Samenvatting
Background: Concerns have been raised regarding adverse cardiovascular outcomes with new therapies for type 2 diabetes (T2DM). The EXAMINE trial studied the effect of the DPP-4 inhibitor alogliptin on major CV events in patients with T2DM and recent acute coronary syndromes. Herein we present data on all cardiac ischemic events and cardiovascular hospitalizations (CVHs) in EXAMINE. Methods: Data from all 5380 patients randomized in EXAMINE were used. The incident rates of MI and unstable angina, coronary revascularization, CVH, and composites of these ischemic endpoints were calculated.
Author information
Authors and Affiliations
Additional information
Boston, MA, Deerfield, IL, Cleveland, OH, Vandoeuvre-lès-Nancy, France, Farmington, CT
About this article
Cite this article
Shimada, Y., Cannon, C., Wilson, C. et al. 21. Cardiac Ischemic Outcomes and Hospitalizations in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome Treated with Alogliptin or Placebo: New Insights from the EXAMINE Trial (13-OR). Ned Tijdschr Diabetol 13, 76–77 (2015). https://doi.org/10.1007/s12467-015-0042-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12467-015-0042-9